IL-23 Antibody (G-6): sc-271280

IL-23 Antibody (G-6) is a mouse monoclonal IgG2a antibody that detects IL-23 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). IL-23 is a crucial cytokine that plays a significant role in the immune response, particularly in the differentiation and maintenance of T helper 17 (Th17) cells, which are essential for combating certain pathogens and are implicated in autoimmune diseases. IL-23 promotes the production of pro-inflammatory cytokines, thereby influencing the inflammatory response and contributing to the pathogenesis of various inflammatory disorders. Notably, IL-23 is composed of two subunits: p19 and p40, with p19 being the unique component that distinguishes IL-23 from IL-12. IL-23′s interaction with its receptor, which shares a subunit with the IL-12 receptor, highlights the complex regulatory mechanisms of the immune system. Elevated IL-23 levels have been associated with conditions such as psoriasis, inflammatory bowel disease, and multiple sclerosis, making IL-23 a critical target for therapeutic intervention. The gene encoding IL-23 is located on human chromosome 12, and understanding IL-23′s function and regulation is vital for developing strategies to modulate immune responses in various diseases. Anti-IL-23 antibody (G-6) is an invaluable tool for researchers studying this cytokine in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IL-23 Antibody (G-6) References:

1. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing.  |  Gaffen, SL., et al. 2014. Nat Rev Immunol. 14: 585-600. PMID: 25145755
2. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.  |  Calcinotto, A., et al. 2018. Nature. 559: 363-369. PMID: 29950727
3. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.  |  Moschen, AR., et al. 2019. Nat Rev Gastroenterol Hepatol. 16: 185-196. PMID: 30478416
4. IL-23- and Imiquimod-Induced Models of Experimental Psoriasis in Mice.  |  Singh, TP., et al. 2019. Curr Protoc Immunol. 125: e71. PMID: 30615272
5. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease.  |  Almradi, A., et al. 2020. BioDrugs. 34: 713-721. PMID: 33105016
6. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis.  |  Fragoulis, GE. and Siebert, S. 2022. Musculoskeletal Care. 20 Suppl 1: S12-S21. PMID: 36069174
7. Human IL-23 is essential for IFN-γ-dependent immunity to mycobacteria.  |  Philippot, Q., et al. 2023. Sci Immunol. 8: eabq5204. PMID: 36763636
8. The Role of IL-23 Inhibitors in Crohn's Disease.  |  Fanizza, J., et al. 2023. J Clin Med. 13: PMID: 38202231
9. IL-23 stabilizes an effector Treg cell program in the tumor microenvironment.  |  Wertheimer, T., et al. 2024. Nat Immunol. 25: 512-524. PMID: 38356059
10. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.  |  Krueger, JG., et al. 2024. Front Immunol. 15: 1331217. PMID: 38686385

The preferred IL-23 antibody is IL-23 Antibody (C-3): sc-271279.